These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30446211)

  • 1. Geroneuroprotectors: Effective Geroprotectors for the Brain.
    Schubert D; Currais A; Goldberg J; Finley K; Petrascheck M; Maher P
    Trends Pharmacol Sci; 2018 Dec; 39(12):1004-1007. PubMed ID: 30446211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease.
    Kou X; Chen N
    Nutrients; 2017 Aug; 9(9):. PubMed ID: 28837083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.
    Kupershmidt L; Amit T; Bar-Am O; Weinreb O; Youdim MB
    Mol Neurobiol; 2012 Aug; 46(1):217-20. PubMed ID: 22847630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery.
    Prior M; Goldberg J; Chiruta C; Farrokhi C; Kopynets M; Roberts AJ; Schubert D
    Alzheimers Dement; 2016 Jun; 12(6):678-86. PubMed ID: 27149904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nerve growth factor in treatment and pathogenesis of Alzheimer's disease.
    Williams BJ; Eriksdotter-Jonhagen M; Granholm AC
    Prog Neurobiol; 2006 Oct; 80(3):114-28. PubMed ID: 17084014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An alternative approach to drug discovery for Alzheimer's disease dementia.
    Schubert D; Maher P
    Future Med Chem; 2012 Sep; 4(13):1681-8. PubMed ID: 22924506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease.
    Venneri A; McGeown WJ; Shanks MF
    Neuroreport; 2005 Feb; 16(2):107-10. PubMed ID: 15671856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease.
    Chen Z; Digiacomo M; Tu Y; Gu Q; Wang S; Yang X; Chu J; Chen Q; Han Y; Chen J; Nesi G; Sestito S; Macchia M; Rapposelli S; Pi R
    Eur J Med Chem; 2017 Jan; 125():784-792. PubMed ID: 27736684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer's Disease Models.
    Zhou W; Zhong G; Fu S; Xie H; Chi T; Li L; Rao X; Zeng S; Xu D; Wang H; Sheng G; Ji X; Liu X; Ji X; Wu D; Zou L; Tortorella M; Zhang K; Hu W
    ACS Chem Neurosci; 2016 Nov; 7(11):1499-1507. PubMed ID: 27504670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.
    Cole GM; Frautschy SA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):140-8. PubMed ID: 20205646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Plants as a Source of Potential Therapeutics for the Treatment of Alzheimer's Disease.
    Maher PA
    Yale J Biol Med; 2020 Jun; 93(2):365-373. PubMed ID: 32607095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease.
    Kwon Y
    Exp Gerontol; 2017 Sep; 95():39-43. PubMed ID: 28528007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases.
    Trudler D; Ghatak S; Lipton SA
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy.
    Plangár I; Zádori D; Klivényi P; Toldi J; Vécsei L
    J Alzheimers Dis; 2011; 24 Suppl 2():199-209. PubMed ID: 21441658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 14th International Conference on Alzheimer's Drug Discovery, 9 - 10 September 2013, in Jersey City, New Jersey.
    Glicksman MA
    Expert Opin Drug Discov; 2014 Feb; 9(2):215-20. PubMed ID: 24444088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Future of Alzheimer's Therapy with the Best Approach.
    Singh H; Chawla V; Bala R; Dureja H
    CNS Neurol Disord Drug Targets; 2020; 19(9):691-697. PubMed ID: 32351189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening strategies to identify HSP70 modulators to treat Alzheimer's disease.
    Repalli J; Meruelo D
    Drug Des Devel Ther; 2015; 9():321-31. PubMed ID: 25609918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease.
    Lan YL; Zhao J; Li S
    J Alzheimers Dis; 2015; 43(4):1137-48. PubMed ID: 25159676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.